Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

265 trials

NCT07609823
Recruiting
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Phase 2 · China · 1 site
Registry update: 30 Jul 2026
NCT07609862
Recruiting
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Phase 1/2 · China · 1 site
Registry update: 30 Jul 2026
2026-525234-39-00
Recruiting
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Phase 1 · Belgium, Germany, Denmark, Spain, France · 17 sites
Registry update: 6 Nov 2026
NCT07685717
Recruiting
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
Phase 2 · United States · 1 site
Registry update: 28 Sept 2026
NCT07566364
Recruiting
Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
Phase 2 · United States · 1 site
Registry update: 12 Aug 2026
2024-519812-15-00
Recruiting
ETCABio - Evaluation of Skin Tests in Biotherapy Allergies
Phase 4 · France · 1 site
Registry update: 19 Mar 2026
NCT06971848
Recruiting
Evaluation of Skin Tests in Biotherapy Allergies
Not applicable · France · 1 site
Registry update: 18 Jun 2026
NCT07024706
Recruiting
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Phase 2 · Austria, Brazil, Czechia, Spain, United Kingdom, Ireland, Italy, Poland, United States · 36 sites
Registry update: 23 Oct 2026
NCT07671378
Recruiting
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
Phase 2 · China · 1 site
Registry update: 26 Jun 2026
NCT07061951
Recruiting
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Phase 2 · United States · 9 sites
Registry update: 6 Oct 2026
NCT07602088
Recruiting
A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic Lymphocytic Leukemia
Not applicable · Romania · 1 site
Registry update: 3 Nov 2026
NCT07582432
Recruiting
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Phase 3 · Czechia, Spain, France, Italy, Poland, United States · 27 sites
Registry update: 1 Oct 2026
NCT07509151
Recruiting
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Phase 3 · Australia, Canada, United Kingdom, United States · 39 sites
Registry update: 6 Oct 2026
NCT07321652
Recruiting
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Phase 3 · United States · 261 sites
Registry update: 3 Nov 2026
NCT07342478
Recruiting
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Phase 3 · Czechia, Germany, Spain, France, Italy, Poland, United States · 54 sites
Registry update: 10 Nov 2026
NCT07271667
Recruiting
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Phase 2 · Spain, Italy, United States · 11 sites
Registry update: 12 Jun 2026
NCT07426484
Recruiting
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Phase 4 · United States · 2 sites
Registry update: 11 Aug 2026
NCT06345027
Recruiting
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Phase 1 · United States · 2 sites
Registry update: 16 Sept 2026
NCT06792994
Recruiting
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
Not applicable · Germany · 2 sites
Registry update: 30 Apr 2026
NCT07392229
Recruiting
Zanubritnib and anti-MAG neuropathy
Phase 2 · Italy · 9 sites
Registry update: 3 Apr 2026

Ordered by registry start date. Freshness and sponsorship never change the order.